Related Experiment Video
Updated: Jul 16, 2026
04:22
Biomarker Identification for Gender Specificity of Alzheimer's Disease Based on the Glial Transcriptome Profiles
Published on: May 20, 2024
Insight and danger in Alzheimer's disease.
S E Starkstein1, R Jorge, R Mizrahi
1School of Psychiatry and Clinical Neurosciences University of Western Australia, WA, Australia. ses@meddent.uwa.edu.au
European Journal of Neurology
|March 29, 2007
Summary
Sixteen percent of Alzheimer
Area of Science:
- Neuroscience
- Gerontology
- Psychiatry
Background:
- Alzheimer's disease (AD) is a progressive neurodegenerative disorder.
- Dangerous behaviors in AD patients can pose risks to themselves and others.
- Understanding correlates of these behaviors is crucial for patient safety and care.
Purpose of the Study:
- To determine the frequency of dangerous behaviors in Alzheimer's disease patients.
- To identify demographic and clinical correlates associated with these behaviors.
Main Methods:
- A consecutive series of 278 Alzheimer's disease patients and 45 healthy controls were assessed.
- Comprehensive psychiatric and neuropsychological evaluations were conducted.
- Caregivers reported the frequency of dangerous behaviors and exposure to dangerous situations.
Main Results:
- Dangerous behaviors occurred in 16% of Alzheimer's disease patients, versus 2% in controls.
- Anosognosia (lack of insight) was associated with a threefold increased risk of dangerous behaviors.
- No significant associations were found with age, education, depression, or suicide ideation.
Conclusions:
- Dangerous behaviors are relatively common in Alzheimer's disease patients.
- Anosognosia is a key clinical correlate, highlighting the importance of insight in AD.
- Findings emphasize the need for vigilant monitoring and management of safety risks in AD.
Related Concept Videos
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:22Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:30Dementia
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual.
The progression of dementia is generally gradual.